Shenzhen Hepalink Pharmaceutical Group Valuation

Is 002399 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002399 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002399 (CN¥10.93) is trading below our estimate of fair value (CN¥328.05)

Significantly Below Fair Value: 002399 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002399?

Key metric: As 002399 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 002399. This is calculated by dividing 002399's market cap by their current revenue.
What is 002399's PS Ratio?
PS Ratio	2.9x
Sales	CN¥5.45b
Market Cap	CN¥14.45b

002399 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.9x
Enterprise Value/EBITDA	59x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 002399's PS Ratio compare to its peers?

The above table shows the PS ratio for 002399 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	3x
600867 Tonghua Dongbao Pharmaceutical	6.7x	24.4%	CN¥16.3b
600420 Shanghai Shyndec Pharmaceutical	1.4x	7.6%	CN¥16.1b
600216 Zhejiang Medicine	1.7x	9.5%	CN¥15.3b
300026 Tianjin Chase Sun PharmaceuticalLtd	2.1x	8.9%	CN¥11.9b
002399 Shenzhen Hepalink Pharmaceutical Group	2.9x	5.5%	CN¥14.5b

Price-To-Sales vs Peers: 002399 is good value based on its Price-To-Sales Ratio (2.9x) compared to the peer average (3x).

Price to Sales Ratio vs Industry

How does 002399's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
600664 Harbin Pharmaceutical Group	0.6x	n/a	US$1.28b
000411 Zhejiang Int'l GroupLtd	0.2x	n/a	US$777.77m
000153 Anhui Fengyuan Pharmaceutical	0.7x	n/a	US$410.69m
600781 FUREN Group PharmaceuticalLtd	0.3x	n/a	US$66.91m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 002399 is good value based on its Price-To-Sales Ratio (2.9x) compared to the CN Pharmaceuticals industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is 002399's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002399 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.9x
Fair PS Ratio	2.4x

Price-To-Sales vs Fair Ratio: 002399 is expensive based on its Price-To-Sales Ratio (2.9x) compared to the estimated Fair Price-To-Sales Ratio (2.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.31

-1.4%

-24.4%

Hunan Jiudian Pharmaceutical

CN¥11.5b

Researches, develops, produces, and sells pharmaceutical products in China and internationally.

300705

CN¥23.30

1.8%

13.1%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.59

-2.4%

12.8%